1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsClinical Research Network on Antimicrobial Resistance (AMR) (RFA-AI-27-005) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the opportunity page linked on this listing to help you evaluate fit faster.
Opportunity Listing - Clinical Research Network on Antimicrobial Resistance Clinical Research Network on Antimicrobial Resistance Agency: National Institutes of Health Assistance Listings: 93. 855 -- Allergy and Infectious Diseases Research Last Updated: May 13, 2026 View version history on Grants.
gov The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by continuing support for a Clinical Research Network on Antimicrobial Resistance (AMR). AMR is a major health challenge that limits treatment options and allows resistant infections to persist.
Individuals with chronic conditions like diabetes and cancer are particularly vulnerable, resulting in increased illness and death as well as higher healthcare costs in the United States. The program aims to design, implement, and manage clinical research addressing key clinical questions in AMR. Research will focus on bacterial and fungal infections associated with AMR.
Areas of emphasis include clinical testing of new antibiotics and other treatments such as bacteriophage therapy, methods optimizing the use of existing antibiotics, evaluating novel diagnostic tests including using diagnostics to refine treatment strategies, and mentoring the next generation of AMR clinical researchers.
Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) For-profit organizations other than small businesses Special district governments City or township governments Public and state institutions of higher education Private institutions of higher education Other Eligible ApplicantsFaith-based or Community-based Organizations;Regional Organizations Grantor contact information Division of Microbiology and Infectious Diseases Please contact via e-mail.
AMRClinicalResearchNetworkContact@mail. nih. gov AMRClinicalResearchNetworkContact@mail.
nih. gov No documents are currently available. Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Eligible applicants include various non-profit organizations, businesses (for-profit and small businesses), government entities, and higher education institutions. Confirm the full requirements in the official notice before applying.
The current listing shows $15,000,000 (total program). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Clinical Research Network on Antimicrobial Resistance (AMR) (RFA-AI-27-005) are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Clinical Research Network on Antimicrobial Resistance (AMR) (RFA-AI-27-005) is funded by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
National Institute of Allergy and Infectious Diseases (NIAID) Resource-Related Research Projects (R24 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This funding opportunity supports resource development projects to advance infectious disease and immunology research. This could include the creation or improvement of models relevant to these fields.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleRFA-AI-28-005 recompetes NIAID's Immune Tolerance Network as a single UM1 cooperative agreement: $27M committed in FY2028, budgets capped at $23M a year in direct costs, a mandatory 7-year project period, one application per institution, and a January 29, 2027 deadline. The winner inherits roughly 20 ongoing trials and about 200 sub-agreements.
Read articleNIAID's RFA-AI-28-024 funds preclinical malaria vaccines, from AI-guided design to cGMP lots, through a phased R61/R33. It allows one application per institution, bars foreign subawards, and excludes GLP tox.
Read article